452 related articles for article (PubMed ID: 29941452)
1. No off-target mutations in functional genome regions of a CRISPR/Cas9-generated monkey model of muscular dystrophy.
Wang S; Ren S; Bai R; Xiao P; Zhou Q; Zhou Y; Zhou Z; Niu Y; Ji W; Chen Y
J Biol Chem; 2018 Jul; 293(30):11654-11658. PubMed ID: 29941452
[TBL] [Abstract][Full Text] [Related]
2. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9.
Chen Y; Zheng Y; Kang Y; Yang W; Niu Y; Guo X; Tu Z; Si C; Wang H; Xing R; Pu X; Yang SH; Li S; Ji W; Li XJ
Hum Mol Genet; 2015 Jul; 24(13):3764-74. PubMed ID: 25859012
[TBL] [Abstract][Full Text] [Related]
3. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C; Amoasii L; Bassel-Duby R; Olson EN
JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
5. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.
Fatehi S; Marks RM; Rok MJ; Perillat L; Ivakine EA; Cohn RD
Hum Gene Ther; 2023 May; 34(9-10):388-403. PubMed ID: 37119122
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
Laurent M; Geoffroy M; Pavani G; Guiraud S
Cells; 2024 May; 13(10):. PubMed ID: 38786024
[TBL] [Abstract][Full Text] [Related]
8. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
[TBL] [Abstract][Full Text] [Related]
9. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.
Himeda CL; Jones TI; Jones PL
Trends Pharmacol Sci; 2016 Apr; 37(4):249-251. PubMed ID: 26917062
[TBL] [Abstract][Full Text] [Related]
10. Trio deep-sequencing does not reveal unexpected off-target and on-target mutations in Cas9-edited rhesus monkeys.
Luo X; He Y; Zhang C; He X; Yan L; Li M; Hu T; Hu Y; Jiang J; Meng X; Ji W; Zhao X; Zheng P; Xu S; Su B
Nat Commun; 2019 Dec; 10(1):5525. PubMed ID: 31797925
[TBL] [Abstract][Full Text] [Related]
11. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
12. Cas9HF1 enhanced specificity in Ustilago maydis.
Zuo W; Depotter JR; Doehlemann G
Fungal Biol; 2020; 124(3-4):228-234. PubMed ID: 32220383
[TBL] [Abstract][Full Text] [Related]
13. FokI-dCas9 mediates high-fidelity genome editing in pigs.
Fisicaro N; Salvaris EJ; Philip GK; Wakefield MJ; Nottle MB; Hawthorne WJ; Cowan PJ
Xenotransplantation; 2020 Jan; 27(1):e12551. PubMed ID: 31407391
[TBL] [Abstract][Full Text] [Related]
14. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
[No Abstract] [Full Text] [Related]
15. Application of the genome editing tool CRISPR/Cas9 in non-human primates.
Luo X; Li M; Su B
Dongwuxue Yanjiu; 2016 Jul; 37(4):214-9. PubMed ID: 27469252
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells.
Morisaka H; Yoshimi K; Okuzaki Y; Gee P; Kunihiro Y; Sonpho E; Xu H; Sasakawa N; Naito Y; Nakada S; Yamamoto T; Sano S; Hotta A; Takeda J; Mashimo T
Nat Commun; 2019 Dec; 10(1):5302. PubMed ID: 31811138
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated genome editing in sea urchins.
Lin CY; Oulhen N; Wessel G; Su YH
Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
19. CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.
Chey YCJ; Arudkumar J; Aartsma-Rus A; Adikusuma F; Thomas PQ
WIREs Mech Dis; 2023 Jan; 15(1):e1580. PubMed ID: 35909075
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.
Sharma G; Sharma AR; Bhattacharya M; Lee SS; Chakraborty C
Mol Ther; 2021 Feb; 29(2):571-586. PubMed ID: 33238136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
